Mistletoe Integrative Concepts for Improving the Quality of Life

Dr. Sophio Badzgaradze, PhD

NMC - New Medical Center, Kutaisi, Georgia

Introduction:
Helixor has been widely used in oncological patients. Due to clinical research, this medicine is given as immunomodulation means and supports prolongation of onco-patients’ life expectancy.

Methods:
Helixors activity mechanism presents cells apoptosis selective elimination. The aforementioned medicine has been used in 32 oncological patient’s i/v and external usage in 2 patients. These patients were selected according to ECOG classification and then number of appreciation of each one was "4". Patients who were treated with chemotherapy first- and second-line treatment and undergone several courses of target therapy; and clinical remission wasn’t received. Patients were given Helixor -1ml during two weeks i/m every second day and then i/v 300 ml (physiological) + 100 ml Helixor 300/60 minutes in frequency i/v infusion.

Results:
Among patients were revealed cancer intoxication elimination and patients health line was increased; Due to the results Helixor usage among palliative patients is successful; among external patients the medicine was injected locally in the cancer. With the patients who were diagnosed with angio-sarcoma, we received academically positive clinical results. As for facial born cancer, the patients are under observation even up to present day.

Conclusion:
The medicine Helixor gives us an opportunity to get prolonged life line among oncological palliative patients